-
- Takeda Receives Clearance from the European Commission for the Proposed Acquisition of Shire plc
- Takeda Pharmaceutical Company Limited (“Takeda”) announces that it has received clearance from the European Commission (the “EC”) for the proposed acquisition of Shire plc (“Shire”) announced on May 8, 2018 (the “Acquisition”). The EC’s approval is con...
- 2018-11-21
-
- Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies
- CAMBRIDGE, MASS. AND INGELHEIM, GERMANY--(Business Wire / Korea Newswire) November 16, 2018 -- Boehringer Ingelheim and Epizyme, Inc. (Nasdaq: EPZM) today announced a new global collaboration focused on the research, development and commercialization of novel s...
- 2018-11-16
-
- Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA®▼ (D/C/F/TAF) in Treatment-Naïve Adults with HIV-1
- GLASGOW, SCOTLAND--(Business Wire / Korea Newswire) October 31, 2018 -- The Janssen Pharmaceutical Companies of Johnson & Johnson today unveiled 96-week results from the pivotal Phase 3 AMBER study of SYMTUZA® (darunavir 800 mg, cobicistat 150 mg, emtricitabin...
- 2018-10-31
-
- Morinaga Milk Study Suggests Infant-Type Human-Residential Bifidobacteria May Benefit Infant Health by Improving Digestion of Peptides in Milk and Grains
- Scientists at Morinaga Milk Industry Co., Ltd. have long theorized that Human-Residential Bifidobacteria (HRB) are superior to non-Human-Residential Bifidobacteria (non-HRB) in promoting good health outcomes. T...
- 2018-10-25
-
- Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC
- Boehringer Ingelheim today announced results from GioTag, a real-world retrospective study which examined the impact of first-line Giotrif®/Gilotrif® (afatinib) followed by osimertinib, in epidermal growth fa...
- 2018-10-22
-
- Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
- Takeda Pharmaceutical Company Limited [TSE:4502] (“Takeda”) today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formu...
- 2018-10-22
-
- Ferring and Evotec Form Strategic Research Alliance in Reproductive Medicine and Women’s Health
- Ferring Pharmaceuticals and Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced a strategic research alliance to discover and develop new small molecule therapies to treat...
- 2018-10-18
-
- Results from Pradaxa® RE-SPECT ESUS® and RE-SPECT CVT® trials to be presented at the 11th World Stroke Congress
- Boehringer Ingelheim today announced that primary results from two key trials, RE-SPECT ESUS® and RE-SPECT CVT®, will be presented at the upcoming World Stroke Congress in Montreal, Canada 17-20 October 2018....
- 2018-10-16
-
- New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018
- Celgene Corporation (NASDAQ:CELG) today announced the results of two post hoc analyses of data from the phase 3 SUNBEAM™ and RADIANCE™ Part B trials, which evaluated the efficacy and safety of ozanimod, a n...
- 2018-10-15
-
- Celgene Announces Phase 3 STYLE Study of OTEZLA® (apremilast) in Moderate to Severe Scalp Psoriasis Met Primary Endpoint
- Celgene Corporation (NASDAQ:CELG) today announced results from the phase 3 STYLE study, which showed that OTEZLA® (apremilast) 30 mg twice daily achieved a highly statistically significant improvement in the p...
- 2018-10-10
-
- Boehringer Ingelheim and Lilly present full results of Trajenta®’s CARMELINA® cardiovascular outcome trial
- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today presented the full results of the long-term cardiovascular outcome trial, CARMELINA®, which studied the impact of Trajenta® (linagliptin) on ca...
- 2018-10-05
-
- New Study Evaluates the Ability of Masimo ORi™ to Help Clinicians Reduce Hyperoxemia in Mechanically Ventilated ICU Patients
- Masimo announced today the findings of an abstract presented at the 2018 Congress of the French Society of Anesthesia and Resuscitation (SFAR) in Paris in which researchers at CHU Angers in France investigated ...
- 2018-10-03
-
- Takeda Establishes Record Date for the Extraordinary General Meeting of Shareholders Company Announces Record Date and Highlights Significant Progress To-Date
- Further to the announcement of the recommended acquisition of Shire plc (“Shire”) on May 8, 2018 (“the Acquisition”), Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda” or the “Company”...
- 2018-10-01
-
- 175 Million Europeans Have Sleep Apnoea, Highlighting Scale of Global Health Crisis
- Roughly 175 million Europeans have obstructive sleep apnoea, according to a late-breaking abstract presented by ResMed today at the European Respiratory Society’s annual ERS Congress in Paris. Leading researc...
- 2018-09-21
-
- MEDTEX: Foresee the Next Wave of Healthcare Revolution
- Taiwan, with high quality medical service and world’s top IT industry, has becoming one of the leaders in global healthcare technology and provider. On November 29 - 30, MEDTEX will focus on 3 key trends: Int...
- 2018-09-18
-
- Clinical trial data for nintedanib in patients with advanced IPF published
- Results from the INSTAGE® trial have been presented at the 2018 European Respiratory Society (ERS) conference in Paris and published in the New England Journal of Medicine. The trial reports clinical data on a...
- 2018-09-17
-
- OptraSCAN® Receives CE Mark Approval for In-Vitro Diagnostics Use
- OptraSCAN®, the leading end-to-end digital pathology solution provider, today announced that their whole-slide scanners have received CE Mark approval for European Standards applicable to “In-Vitro Diagnosti...
- 2018-09-14
-
- New Study Investigates the Utility of Home Monitoring Using Masimo SET® Pulse Oximetry to Screen Children with Down Syndrome for Risk of Obstructive Sleep Apnea Prior to Diagnostic Multichannel Sleep Studies
- Masimo announced today the findings of a recently published study in which researchers investigated whether home pulse oximetry monitoring might be a useful initial screening method of determining which childre...
- 2018-08-14
-
- Graminex® LLC successfully challenges Serelys’ patents for use of pollen extracts in treating women's PMS and menopausal symptoms
- Graminex® LLC is pleased to announce the US Patent Office has rejected Serelys’ patents for use of its pollen extracts in treating women's PMS and menopausal symptoms. In parallel reexamination proceedings a...
- 2018-08-03
-
- Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK Inhibitor Naïve
- Takeda Pharmaceutical Company Limited today announced that the global, randomized, Phase 3 ALTA-1L (ALK in Lung Cancer Trial of AP26113 in 1st Line) trial met its primary endpoint at the first pre-specified int...
- 2018-07-26
- 기획특집 2 - 미세먼지더보기
-
-
- 도로포장 신기술로 미세먼지 잡는다
- 서울시가 미세먼지의 원인이 되는 질소산화물 정화기능이 있는 ‘광촉매’를 활용한 도로포장 신기술을 전국 최초로 도입한다고 28일 밝혔다. 이 기술은 도로 포장면에 광촉매를 뿌려 자동차 배기가스의 주성분인 질소산화물을 분해하는 방식으로, 도로 위 미세먼지를 줄일 수 있을 것으로 기대된다. 이와...
-
- 미세먼지 영향, 알레르기 비염 환자도 급증했다
- 보건복지부(박능후 장관)가 '통계로 보는 사회보장 2017'을 발간한다고 6일 밝혔다. 보건복지부는 국민의 삶의 질과 관련된 각 분야를 조사해 가족, 환경, 교육, 근로, 건강 등 11개 분야와 262개 지표로 구성했다. 이번에 공개한 통계 중에서 국민 기초생활보장제도 수급률이 눈에 띄게 상승했다. 2009년부터 5...
-
- 전국 미세먼지 나쁨 예보, 노약자·임산부·기저질환자 특히 주의
- [트리니티메디컬뉴스=신민철기자] 질병관리본부(본부장 정은경)는 23일 봄철 미세먼지 농도 나쁨이 예보된 가운데 어린이, 어르신, 임산부, 기저질환자(호흡기질환, 심뇌혈관질환, 천식)는 건강보호에 더 각별한 주의를 기울여 줄 것을 당부했다. 미세먼지는 피부와 눈, 코 또는 인후 점막에 직접 접촉해 물리적 자극을 유발하고, 크기가 작아...
-
환경부, 미세먼지 환경 기준 미국 일본 수준으로 강화
-
서울시, ‘미세먼지 측정소’ 20m 이내로 이전
